Search

Your search keyword '"Bonavita, Simona"' showing total 17 results
Start Over Author "Bonavita, Simona" Journal journal of the neurological sciences
17 results on '"Bonavita, Simona"'

1. MRI activity and extended interval of Natalizumab dosing regimen: a multicentre Italian study

Author

De Mercanti, Stefania Federica, Signori, Alessio, Cordioli, Cinzia, Signoriello, Elisabetta, Lus, Giacomo, Bonavita, Simona, Abbadessa, Gianmarco, Lavorgna, Luigi, Maniscalco, Giorgia Teresa, Curti, Erica, Lorefice, Lorena, Cocco, Eleonora, Nociti, Viviana, Mirabella, Massimiliano, Baroncini, Damiano, Mataluni, Giorgia, Landi, Doriana, Petruzzo, Martina, Lanzillo, Roberta, Gandoglia, Ilaria, Laroni, Alice, Frangiamore, Rita, Sartori, Arianna, Cavalla, Paola, Costantini, Gianfranco, Capra, Ruggero, Sormani, Maria Pia, and Clerico, Marinella

Published
2021
Full Text
View/download PDF

2. Cardiovascular autonomic individual profile of relapsing-remitting multiple sclerosis patients and risk of extending cardiac monitoring after first dose fingolimod

Author

Vanoli, Emilio, Montano, Nicola, De Angelis, Giuseppe, Badilini, Fabio, Mirabella, Massimiliano, Bonavita, Simona, Patti, Francesco, Bianco, Assunta, Sparaco, Maddalena, Chisari, Clara, Laroni, Alice, Frigerio, Francesca, Bartezaghi, Marta, Rossi, Silvia, Turrini, Renato, and Mancardi, Gianluigi

Published
2019
Full Text
View/download PDF

10. Ocrelizumab treatment in multiple sclerosis: Prospective real world observational multi-center study in Campania, Italy

Author

Lanzillo, Roberta, Carotenuto, Antonio, Moccia, Marcello, Capasso, Nicola, Petracca, Maria, Spiezia, Antonio, Maniscalco, Giorgia, Di Gregorio, Maria, Sinisi, Leonardo, Iodice, Rosa, Dubbioso, Raffaele, Bonavita, Simona, Miele, Giuseppina, Lus, Giacomo, Signoriello, Elisabetta, Mario, Fratta, Bisecco, Alvino, Felice, Romano, Tedeschi, Gioacchino, and Morra, Vincenzo Brescia

Published
2021
Full Text
View/download PDF

12. Digital work engagement among Italian neurologists

Author

Brigo, Francesco, Sormani, Mariapia, Clerico, Marinella, Ponzano, Marta, Abbadessa, Gianmarco, Cossu, Giovanni, Trojsi, Francesca, Colucci, Fabiana, Tortorella, Carla, Miele, Giuseppina, Bozzali, Marco, Sparaco, Maddalena, Leocani, Letizia, Lanzillo, Roberta, Tedeschi, Gioacchino, Bonavita, Simona, and Lavorgna, Luigi

Published
2021
Full Text
View/download PDF

15. Correlation between fatigue and brain atrophy and lesion load in multiple sclerosis patients independent of disability

Author

Tedeschi, Gioacchino, Dinacci, Daria, Lavorgna, Luigi, Prinster, Anna, Savettieri, Giovanni, Quattrone, Aldo, Livrea, Paolo, Messina, Corrado, Reggio, Arturo, Servillo, Giovanna, Bresciamorra, Vincenzo, Orefice, Giuseppe, Paciello, Marcantonio, Brunetti, Arturo, Paolillo, Andrea, Coniglio, Gabriella, Bonavita, Simona, Di Costanzo, Alfonso, Bellacosa, Alessandra, Valentino, Paola, Quarantelli, Mario, Patti, Francesco, Salemi, Giuseppe, Cammarata, Enrico, Simone, Isabella, Salvatore, Marco, Bonavita, Vincenzo, and Alfano, Bruno

Published
2007
Full Text
View/download PDF

16. MRI activity and extended interval of Natalizumab dosing regimen: a multicentre Italian study

Author

Doriana Landi, Gianmarco Abbadessa, Gianfranco Costantini, Giacomo Lus, Stefania Federica De Mercanti, Cinzia Cordioli, Simona Bonavita, Giorgia Mataluni, Massimiliano Mirabella, Maria Pia Sormani, Ilaria Gandoglia, Giorgia Teresa Maniscalco, Martina Petruzzo, Rita Frangiamore, Eleonora Cocco, Erica Curti, Damiano Baroncini, Ruggero Capra, Elisabetta Signoriello, Paola Cavalla, Luigi Lavorgna, Lorena Lorefice, Alice Laroni, Marinella Clerico, Viviana Nociti, Alessio Signori, Arianna Sartori, Roberta Lanzillo, De Mercanti, Stefania Federica, Signori, Alessio, Cordioli, Cinzia, Signoriello, Elisabetta, Lus, Giacomo, Bonavita, Simona, Abbadessa, Gianmarco, Lavorgna, Luigi, Maniscalco, Giorgia Teresa, Curti, Erica, Lorefice, Lorena, Cocco, Eleonora, Nociti, Viviana, Mirabella, Massimiliano, Baroncini, Damiano, Mataluni, Giorgia, Landi, Doriana, Petruzzo, Martina, Lanzillo, Roberta, Gandoglia, Ilaria, Laroni, Alice, Frangiamore, Rita, Sartori, Arianna, Cavalla, Paola, Costantini, Gianfranco, Capra, Ruggero, Sormani, Maria Pia, Clerico, Marinella, De Mercanti, S. F., Signori, A., Cordioli, C., Signoriello, E., Lus, G., Bonavita, S., Abbadessa, G., Lavorgna, L., Maniscalco, G. T., Curti, E., Lorefice, L., Cocco, E., Nociti, V., Mirabella, M., Baroncini, D., Mataluni, G., Landi, D., Petruzzo, M., Lanzillo, R., Gandoglia, I., Laroni, A., Frangiamore, R., Sartori, A., Cavalla, P., Costantini, G., Capra, R., Sormani, M. P., and Clerico, M.

Subjects
medicine.medical_specialty, Efficacy, Progressive Multifocal, Relapsing-Remitting, Settore MED/26, law.invention, Multiple sclerosis, 03 medical and health sciences, Magnetic resonance imaging, Immunologic Factor, Multiple Sclerosis, Relapsing-Remitting, 0302 clinical medicine, Natalizumab, Randomized controlled trial, Leukoencephalopathy, Retrospective Studie, law, Internal medicine, Multiple Sclerosi, Humans, Immunologic Factors, Medicine, 030212 general & internal medicine, Dosing, Retrospective Studies, Extended dose, medicine.diagnostic_test, business.industry, Progressive multifocal leukoencephalopathy, Leukoencephalopathy, Progressive Multifocal, Retrospective cohort study, medicine.disease, Settore MED/26 - NEUROLOGIA, Regimen, Italy, Neurology, Magnetic Resonance Imaging, Multiple Sclerosis, Neurology (clinical), business, 030217 neurology & neurosurgery, Human, medicine.drug
Abstract

Background: To minimize the risk of Progressive Multifocal Leukoencephalopathy and rebound in JCV-positive multiple sclerosis (MS) patients after 24 natalizumab doses, it has been proposed to extend the administrations interval. The objective is to evaluate the EID efficacy on MRI activity compared with the standard interval dosing (SID). Methods: Observational, multicentre, retrospective cohort study, starting from the 24th natalizumab infusion to the loss of follow-up or 2 years after baseline. Three hundred and sixteen patients were enrolled. The median dose interval (MDI) following the 24th infusion was 5 weeks, with a bimodal distribution (modes at 4 and 6 weeks). Patients were grouped into 2 categories according to the mean number of weeks between doses: < 5 weeks, SID; ≥ 5 weeks, EID. Results: One hundred and eighty-seven patients were in the SID group (MDI = 4.5 weeks) and 129 in the EID group (MDI 6.1 weeks). The risk to develop active lesions on MRI is similar in SID and EID groups during the 6 and 12 months after the 24th natalizumab infusion, respectively 4.27% (95% CI:0.84–7.70) vs 4.71% (95% CI:0.16–9.25%) [p = 0.89] and 8.50% (95% CI:4.05–12.95) vs 6.55% (95% CI:2.11–11.00%) [p = 0.56]. The EID regimen does not appear to increase the occurrence of MRI activity during follow-up. Conclusion: There is no evidence of the reduced efficacy of natalizumab in an EID setting regarding the MRI activity. This observation supports the need for a bigger randomized study to assess the need to change the standard of the natalizumab dosing schedule, to better manage JCV-positive patients.

Published
2021

17. Prevalence of patient-reported dysphagia in multiple sclerosis patients: an Italian multicenter study (using the DYMUS questionnaire)

Author

Claudio Solaro, Claudio Gasperini, Valentina Zipoli, C. Rezzani, Erika Trabucco, Pasquin Rossi, L. Finamore, Pietro Annovazzi, A. Ghezzi, M. L. Stromillo, Maria Pia Amato, Roberto Bergamaschi, Jessica Frau, Simona Bonavita, Davide Maimone, Marta Giannini, M. Rottoli, Emanuele D'Amico, Maria Grazia Grasso, Domenico A. Restivo, M. Della Corte, Lorena Lorefice, Emilio Portaccio, Francesco Patti, Solaro, C, Rezzani, C, Trabucco, E, Amato, Mp, Zipoli, V, Portaccio, E, Giannini, M, Patti, F, D'Amico, E, Frau, J, Lorefice, L, Bonavita, Simona, Corte, Md, Grasso, Mg, Finamore, L, Ghezzi, A, Annovazzi, P, Rottoli, M, Gasperini, C, Restivo, D, Maimone, D, Rossi, P, Stromillo, Ml, and Bergamaschi, R.

Subjects
Adult, Male, Pediatrics, medicine.medical_specialty, Multiple Sclerosis, Design data, Adolescent, Disease duration, Statistics as Topic, QUESTIONNAIRE, Disease, DYSPHAGIA, Disease course, Disability Evaluation, Young Adult, Surveys and Questionnaires, otorhinolaryngologic diseases, medicine, Prevalence, Humans, Child, business.industry, Multiple sclerosis, Infant, Middle Aged, medicine.disease, Dysphagia, Clinical Practice, Cross-Sectional Studies, Neurology, Multicenter study, Italy, Child, Preschool, Physical therapy, Female, Neurology (clinical), Self Report, medicine.symptom, business, Deglutition Disorders
Abstract

OBJECTIVE: Multiple sclerosis (MS) is an inflammatory disease of the central nervous system (CNS) with a chronic course. Dysphagia represents one of the current challenges in clinical practice for the management of MS patients. Dysphagia starts to appear in mildly impaired MS subjects (EDSS 2-3) and becomes increasingly common in the most severely disabled subjects (EDSS 8-9). The aim of the present study was to evaluate the frequency and characteristics of patient-reported dysphagia in MS patients with a multicenter study using the recently developed DYMUS (DYsphagia in MUltiple Sclerosis) questionnaire. DESIGN: Data were collected in a multi-centre, cross-sectional study using a face-to-face structured questionnaire for clinical characteristics and the DYMUS questionnaire. RESULTS: 1875 patients were interviewed. The current study has shown a correlation between patient-reported dysphagia and EDSS and disease course but not with age, gender and disease duration. Questionnaires were divided into "patient-reported dysphagia-yes" (587, 31.3%) and "patient-reported dysphagia-no" (1288, 68.7%). Compared with the patient-reported dysphagia-no group, patients in patient-reported dysphagia-yes group had higher EDSS score (mean EDSS 4.6 vs. 2.8; p

Published
2012

Catalog

Books, media, physical & digital resources
See catalog results